Neurotech starts pivotal autism trial as US clearance and funding bolster NTI164 program
NTI: $0.018 -5.26% · MC: $31M
Neurotech International has dosed the first patient in its Phase 3 autism trial of NTI164, with all Australian sites initiated and up to 200 participants planned. The company also received US FDA clearance to begin a proposed clinical program and patent allowances, while securing a loan and placement commitments to support development; it says current funding is expected to last through the trial’s top-line data readout.

Comments